PH12020551263A1 - Sustained release formulations of bempedoic acid - Google Patents

Sustained release formulations of bempedoic acid

Info

Publication number
PH12020551263A1
PH12020551263A1 PH12020551263A PH12020551263A PH12020551263A1 PH 12020551263 A1 PH12020551263 A1 PH 12020551263A1 PH 12020551263 A PH12020551263 A PH 12020551263A PH 12020551263 A PH12020551263 A PH 12020551263A PH 12020551263 A1 PH12020551263 A1 PH 12020551263A1
Authority
PH
Philippines
Prior art keywords
bempedoic acid
sustained release
release formulations
bempedoic
methods
Prior art date
Application number
PH12020551263A
Other languages
English (en)
Inventor
Narendra Dhanraj Lalwani
Mohamed Abdelnasser
Stephen Lawrence Pinkosky
Clay Thomas Cramer
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of PH12020551263A1 publication Critical patent/PH12020551263A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12020551263A 2018-02-16 2020-08-17 Sustained release formulations of bempedoic acid PH12020551263A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862710417P 2018-02-16 2018-02-16
US201862774083P 2018-11-30 2018-11-30
PCT/US2019/018356 WO2019161307A1 (fr) 2018-02-16 2019-02-15 Formulations à libération prolongée d'acide bempedoique

Publications (1)

Publication Number Publication Date
PH12020551263A1 true PH12020551263A1 (en) 2021-07-05

Family

ID=65685995

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551263A PH12020551263A1 (en) 2018-02-16 2020-08-17 Sustained release formulations of bempedoic acid

Country Status (15)

Country Link
EP (1) EP3752133A1 (fr)
JP (1) JP2021513987A (fr)
KR (1) KR20200123181A (fr)
CN (1) CN111971030A (fr)
AU (1) AU2019221765A1 (fr)
BR (1) BR112020016494A2 (fr)
CA (1) CA3091259A1 (fr)
CL (1) CL2020002101A1 (fr)
IL (1) IL276689A (fr)
MX (1) MX2020008527A (fr)
PH (1) PH12020551263A1 (fr)
RU (1) RU2020129191A (fr)
SG (1) SG11202007825XA (fr)
TW (1) TW202000191A (fr)
WO (1) WO2019161307A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112437765A (zh) 2019-06-21 2021-03-02 艾斯柏伦治疗公司 贝派地酸的盐形式及其使用方法
CN111381270B (zh) * 2020-03-06 2023-04-18 广西田东力源宝科技有限公司 一种利用同位素示踪监控肥料分布的方法
WO2022256378A1 (fr) 2021-06-02 2022-12-08 Esperion Therapeutics, Inc. Compositions contenant de l'acide bempedoïque et du tolvaptan et thérapies les utilisant
AU2022342749A1 (en) 2021-09-13 2024-03-21 Synthon B.V. Pharmaceutical composition of bempedoic acid
WO2023093807A1 (fr) * 2021-11-24 2023-06-01 南京昕瑞再生医药科技有限公司 Composé et méthode de traitement de maladies hépatiques
WO2023217694A1 (fr) * 2022-05-09 2023-11-16 Renata Pharmaceutical (Ireland) Ltd Composition pharmaceutique d'acide bempédoïque

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ES2594340T3 (es) 2003-01-23 2016-12-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
CN101669948A (zh) * 2008-09-11 2010-03-17 北京科信必成医药科技发展有限公司 一种烟酸和洛伐他汀的缓释片及其制备方法
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (fr) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et d'un inhibiteur de citrate lyase d'atp–activateur d'ampk
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Also Published As

Publication number Publication date
CA3091259A1 (fr) 2019-08-22
IL276689A (en) 2020-09-30
TW202000191A (zh) 2020-01-01
AU2019221765A1 (en) 2020-09-10
BR112020016494A2 (pt) 2020-12-15
WO2019161307A1 (fr) 2019-08-22
JP2021513987A (ja) 2021-06-03
EP3752133A1 (fr) 2020-12-23
CN111971030A (zh) 2020-11-20
SG11202007825XA (en) 2020-09-29
MX2020008527A (es) 2020-09-18
RU2020129191A (ru) 2022-03-16
CL2020002101A1 (es) 2021-02-19
KR20200123181A (ko) 2020-10-28

Similar Documents

Publication Publication Date Title
PH12020551263A1 (en) Sustained release formulations of bempedoic acid
MX2022007432A (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino.
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
EP4218735A3 (fr) Formulations à libération modifiée de gamma-hydroxybutyrate ayant une pharmacocinétique améliorée
EP4219532A3 (fr) Compositions et procédés pour une thérapie génique transitoire à stabilité améliorée
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
AU2018335389A1 (en) Nanofiber structures and methods of use thereof
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
EA201991431A1 (ru) УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ
MX2020012765A (es) Métodos y compuestos de ácido nucleico modificado con lípidos.
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
CR20200239A (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este
MY192216A (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
PH12020551716A1 (en) Anti-ror antibody constructs
MX2018015280A (es) Conjugados de anticuerpo y farmaco anti-egfr.
MY182793A (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
MY192425A (en) Polymorphs
MX2018015284A (es) Conjugados de anticuerpo anti-egfr y fármaco.
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
MX2020001885A (es) Formulaciones de daptomicina.
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
MY191297A (en) Oral solid formulation containing irinotecan and method of preparing the same
EP4285930A3 (fr) Formulations de protéines
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.